Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Arthritis & Rheumatism

• Publication date

  1993-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ART.1780360812PMID 8393677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating plasma receptors for tumour necrosis factor in Malawian children with severe falciparum malaria.

  1993cited by this paper
• Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.

  1992cited by this paper
• Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.

  1991cited by this paper
• Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis.

  1991cited by this paper
• Cytokine Assays: Role in Evaluation of the Pathogenesis of Autoimmunity

  1991cited by this paper
• Independent regulation of 55‐kDa and 75‐kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes

  1991cited by this paper
• A specific receptor antagonist for interleukin 1 prevents Escherichia coli‐induced shock in rabbits

  1991cited by this paper
• Soluble cytokine receptors: their role in immunoregulation

  1991cited by this paper
• Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

  1990cited by this paper
• Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor.

  1990cited by this paper
• Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors.

  1990cited by this paper
• Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans.

  1990cited by this paper
• Soluble forms of tumor necrosis factor receptors (TNF‐Rs). The cDNA for the type I TNF‐R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.

  1990cited by this paper
• Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

  1990cited by this paper
• Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity.

  1990cited by this paper
• Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes.

  1990cited by this paper
• Shedding of tumor necrosis factor receptors by activated human neutrophils

  1990cited by this paper
• Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes

  1990cited by this paper
• Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

  1989cited by this paper
• Glomerular basement membrane-containing immune complexes stimulate tumor necrosis factor and interleukin-1 production by human monocytes.

  1989cited by this paper
• Isolation and characterization of a tumor necrosis factor binding protein from urine

  1989cited by this paper
• Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury.

  1989cited by this paper
• Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo.

  1989cited by this paper
• A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.

  1989cited by this paper
• Tumor necrosis factor in the serum of patients with systemic lupus erythematosus.

  1989cited by this paper
• Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha).

  1989cited by this paper
• Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1.

  1989cited by this paper
• Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.

  1989cited by this paper
• Development and Assessment of a Computerized Index of Clinical Disease Activity in Systemic Lupus Erythematosus

  1988cited by this paper
• Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1.

  1988cited by this paper
• Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG).

  1988cited by this paper
• Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis

  1988cited by this paper
• Stimulation of the hyaluronic acid levels of human synovial fibroblasts by recombinant human tumor necrosis factor α, tumor necrosis factor β (lymphotoxin), interleukin-1α, and interleukin-1β

  1988cited by this paper
• Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis.

  1988cited by this paper
• Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

  1988cited by this paper
• Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis.

  1988cited by this paper
• Stimulation of the hyaluronic acid levels of human synovial fibroblasts by recombinant human tumor necrosis factor alpha, tumor necrosis factor beta (lymphotoxin), interleukin-1 alpha, and interleukin-1 beta.

  1988cited by this paper
• Soluble interleukin-2 receptors in systemic lupus erythematosus.

  1988cited by this paper
• HLA-DR expression in the vascular lesion and circulating T lymphocytes of patients with giant cell arteritis.

  1988cited by this paper
• Tumour necrosis factor in synovial exudates.

  1988cited by this paper
• Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.

  1988cited by this paper
• Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption.

  1987cited by this paper
• Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.

  1987cited by this paper
• Effect of tumor necrosis factor alpha on mitogen-activated human B cells

  1987cited by this paper
• Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s).

  1986cited by this paper
• Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein.

  1985cited by this paper
• Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever

  1985cited by this paper
• Preparations of lymphotoxin induce resistance to their own cytotoxic effect.

  1984cited by this paper
• Immune interferon in serum and synovial fluid in rheumatoid arthritis and related disorders.

  1983cited by this paper
• The 1982 revised criteria for the classification of systemic lupus erythematosus.

  1982cited by this paper
• Useful laboratory measurements in the management of systemic lupus erythematosus.

  1982cited by this paper

• Advances in Radiation Therapy for Primary Liver Cancer.

  2023cites this paper
• The Effect of Stereotactic Body Radiation Therapy for Hepatocellular Cancer on Regional Hepatic Liver Function.

  2022cites this paper
• Tumor necrosis factor‑α in systemic lupus erythematosus: Structure, function and therapeutic implications (Review).

  2022cites this paper
• Omega-3 fatty acids: Current insights into mechanisms of action in systemic lupus erythematosus

  2022cites this paper
• Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors

  2022cites this paper
• Tumor necrosis factor receptor 2 and anti-ribosomal P antibodies as biomarkers in juvenile neuropsychiatric systemic lupus erythematosus

  2022cites this paper
• Alternative Splicing: A New Cause and Potential Therapeutic Target in Autoimmune Disease

  2021cites this paper
• T-cell biology, tolerance, and regulation

  2021cites this paper
• Genetic Predisposition, Humans

  2020cites this paper
• Autoinflammatory Diseases: From Genes To Bedside

  2020cites this paper
• Complements as a Predictive Biomarker of Lupus Nephritis in Female Patients with Systemic Lupus Erythematosus

  2020influential citation
• TNFR1 and the TNFα axis as a targetable mediator of liver injury from stereotactic body radiation therapy

  2020cites this paper
• Autonomous lab-on-a-chip generic architecture for disposables with integrated actuation

  2019cites this paper
• Blood Levels of Tumor Necrosis Factor Alpha and Its Type 2 Receptor Are Elevated in Patients with Boston Type I Keratoprosthesis

  2019cites this paper
• Dihydroartemisinin regulates the immune system by promotion of CD8+ T lymphocytes and suppression of B cell responses

  2019cites this paper
• TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus

  2018cites this paper
• Adipokines, tumor necrosis factor and its receptors in female patients with systemic lupus erythematosus

  2017cites this paper
• Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease

  2017cites this paper
• TNFR1 and TNFR2 Expression and Induction on Human Treg Cells from Type 1 Diabetic Subjects

  2015cites this paper
• Differential regulation of TNF receptors in maternal leukocytes is associated with severe preterm preeclampsia

  2015cites this paper
• Etanercept in refractory lupus arthritis: An observational study.

  2015cites this paper
• HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response

  2015cites this paper
• Shedding of TNF receptor 2 by effector CD8+ T cells by ADAM17 is important for regulating TNF‐α availability during influenza infection

  2015cites this paper
• Cytokines: Names and Numbers You Should Care About.

  2015cites this paper
• Determination of soluble tumor necrosis factor receptor 2 produced by alternative splicing.

  2014cites this paper
• Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIα in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma

  2014cites this paper
• Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside

  2014cites this paper
• Targeted Therapies in Systemic Lupus Erythematosus: A State-of-the Art Review

  2013cites this paper
• Etanercept‐induced Wegener granulomatosis in a patient with rheumatoid arthritis

  2013cites this paper
• The effects of elective total knee arthroplasty on the activation of markers of inflammation, coagulation and endothelial dysfunction

  2013cites this paper
• Targeted Therapies in Systemic Lupus Erythematosus : A State-ofthe-Art

  2013cites this paper
• Protein therapeutics targeted at the TNF superfamily.

  2013cites this paper
• Serum cytokine profile in patients with active lupus nephritis.

  2012influential citation
• Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFβ1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3

  2011cites this paper
• VERSUCH DER HERSTELLUNG EINES MONOKLONALEN MAUS-ANTI-MAUS-ANTIKÖRPERS GEGEN DEN TNFR2 MIT AGONISTISCHEN ODER ANTAGONISTISCHEN EIGENSCHAFTEN

  2011cites this paper
• The ‘Connective Tissue Diseases’

  2010cites this paper
• Multidimensional protein fractionation of blood proteins coupled to data-independent nanoLC-MS/MS analysis.

  2010cites this paper
• Serum Levels and in Vitro Production of Th1- and Th2-Type Cytokines by Peripheral Blood Mononuclear Cells in Patients Suffering from Systemic Lupus Erythematosus

  2010cites this paper
• Altered Expression of TNF-α Signaling Pathway Proteins in Systemic Lupus Erythematosus

  2010influential citation
• A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs

  2010cites this paper
• Serum cytokine levels in patients with chronic low back pain due to herniated disc: analytical cross-sectional study

  2010cites this paper
• IFNsVascular Damage and Synthesizes Type I Systemic Lupus Erythematosus Induces Neutrophils Isolated from Patients with A Distinct Subset of Proinflammatory

  2010cites this paper
• Serum cytokine levels in patients with chronic low back pain due to herniated disc: analytical cross-sectional study Concentrações plasmáticas de citocinas em pacientes com lombalgia crônica por hérnia de disco: estudo transversal analítico

  2010cites this paper
• Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4

  2010cites this paper
• The role of TNF receptor type 2 on myeloid cells in sepsis - functional analysis

  2010cites this paper
• The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus1

  2009cites this paper
• Inflammation in Murine Lupus Cardiometabolic Risk and Renal Agonist Pioglitazone Improves γ Receptor The Peroxisome Proliferator-Activated Kretzler

  2009cites this paper
• This information is current as Inflammation in Murine Lupus Cardiometabolic Risk and Renal Agonist Pioglitazone Improves γ Receptor The Peroxisome Proliferator-Activated

  2009cites this paper
• Lupus and T cells.

  2009cites this paper
• Lupus and T Cells

  2009cites this paper
• Antibody-based therapies in systemic lupus erythematosus.

  2009cites this paper
• Crucial Role of TNF Receptors 1 and 2 in the Control of Polymicrobial Sepsis1

  2009cites this paper
• The pathophysiology of hypertension in systemic lupus erythematosus.

  2009cites this paper
• The Rheumatology Polymyalgia rheumatica and biopsy-proven giant cell arteritis exhibit different

  2008cites this paper
• The role of tumor necrosis factor-alpha in systemic lupus erythematosus

  2008cites this paper
• Linear Scleroderma en Coup de Sabre and Brain

  2008cites this paper
• Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study.

  2008cites this paper
• Linear Scleroderma en Coup de Sabre and Brain

  2008cites this paper
• Linear Scleroderma en Coup de Sabre and Brain

  2008cites this paper
• A study on the TNF-α system in Caucasian Spanish patients with alcoholic liver disease

  2008cites this paper
• A study on the TNF-alpha system in Caucasian Spanish patients with alcoholic liver disease.

  2008cites this paper
• Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico

  2008cites this paper
• Triglyceride and high-density lipoprotein levels as the markers of disease activity and their association with TNF-α and TNF receptor system in systemic lupus erythematosus

  2007cites this paper
• Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.

  2006cites this paper
• The role of soluble tumor necrosis factor receptor types I and II and tumor necrosis factor-alpha in malaria during pregnancy.

  2006cites this paper
• Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus.

  2006cites this paper
• The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus.

  2006cites this paper
• Host Immune Status and Incidence of Hepatocellular Carcinoma among Subjects Infected with Hepatitis C Virus: A Nested Case-Control Study in Japan

  2006cites this paper
• The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis

  2005cites this paper
• Tumor necrosis factor alpha (TNF-α) and sepsis: Evidence for a role in host defense

  2005cites this paper
• Current state of tumour necrosis factor α blockade in Wegener’s granulomatosis

  2005cites this paper
• Regulation of apoptosis in immune cells

  2005cites this paper
• Colocalization of endogenous TNF with a functional intracellular splice form of human TNF receptor type 2

  2005cites this paper
• Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

  2005cites this paper
• Tumour necrosis factor α is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus

  2005cites this paper
• New treatments for SLE: cell-depleting and anti-cytokine therapies.

  2005cites this paper
• Activation of tumor necrosis factor — α system in HIV-1 infection: Association with markers of immune activation

  2005cites this paper
• SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR ( p 75 ) FUSION PROTEIN ( ENBREL ) AS A THERAPY FOR ' RHEUMATOID ARTHRITIS

  2005cites this paper
• A radioreceptor assay for TNFα-binding proteins

  2004cites this paper
• Immunological intervention reveals reciprocal roles for tumor necrosis factor-α and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus

  2004cites this paper
• The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications

  2004cites this paper
• Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus

  2004cites this paper
• Biomarkers in systemic lupus erythematosus: II. Markers of disease activity.

  2004cites this paper
• Decreased Binding of Annexin V to Endothelial Cells: A Potential Mechanism in Atherothrombosis of Patients With Systemic Lupus Erythematosus

  2004cites this paper
• Biomarkers in systemic lupus erythematosus

  2004cites this paper
• Cell-cell contact in chronic inflammation: the importance to cytokine regulation in tissue destruction and repair

  2004cites this paper
• The Skin Cytokine Network

  2004cites this paper
• Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2.

  2004cites this paper
• Pregnancy, cytokines, and disease activity in systemic lupus erythematosus.

  2004cites this paper
• 44 – PATHOPHYSIOLOGY OF DRUG-INDUCED LUPUS

  2004cites this paper
• Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

  2004cites this paper
• The effect of Interleukin-10 and of Interleukin-12 on the anti-double-stranded DNA antibody production by the blood lymphocytes of patients with systemic lupus erythematosus.

  2003cites this paper
• Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis.

  2003cites this paper
• Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.

  2003cites this paper
• TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease.

  2003cites this paper
• TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease

  2003cites this paper
• A lupus-like syndrome associated with infliximab therapy.

  2003cites this paper
• Tumor necrosis factor receptor 2 microsatellite and exon 6 polymorphisms in rheumatoid arthritis in Taiwan.

  2003cites this paper
• The Journal of Rheumatology rheumatoid arthritis in Taiwan. Tumor necrosis factor receptor 2 microsatellite and exon 6 polymorphisms in

  2003cites this paper
• Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease.

  2003cites this paper